RANITIDINE-DARNITSA

Antiulcer drug, Histamine H2-receptor antagonist

learn more

RANITIDINE-DARNITSA

Antiulcer drug, Histamine H2-receptor antagonist

The drug reduces basal and stimulated secretion of hydrochloric acid, reducing the amount of gastric juices caused by stimulation of baroreceptors (stretching of the stomach), nutritional load, action of hormones and biogenic stimulators (gastrin, histamine, pentagastrin, caffeine).

Indications for use:

  • peptic ulcer of the stomach and duodenum, not associated with Helicobacter pylori (in exacerbation phase), including ulcers, associated with non-steroidal anti-inflammatory drug administration (NSAIDs);
  • functional dyspepsia ;
  • chronic gastritis with increased stomach acid-forming function in the acute stage ;
  • gastroesophageal reflux disease (to relieve symptoms ) or reflux esophagitis.
More in instructions (Ukrainian version)
INN
Ranitidin
Package
150 mg,10 x 150 mg
Form of release
Tablets
Appointment
Gastrointestinal diseases
АТС class
A02B A02

Other forms of release

  • RANITIDINE-DARNITSA 150 mg, 20 x 150 mg

    RANITIDINE-DARNITSA

See also

Specialized publications intended for medical institutions and doctors Limitations in obtaining information